Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.

Zhang W, Zhou H, Yu Y, Li J, Li H, Jiang D, Chen Z, Yang D, Xu Z, Yu Z.

Onco Targets Ther. 2016 Jun 2;9:3359-68. doi: 10.2147/OTT.S100936. eCollection 2016.

3.

Cellular Recognition and Repair of Monofunctional-Intercalative Platinum--DNA Adducts.

Liu F, Suryadi J, Bierbach U.

Chem Res Toxicol. 2015 Nov 16;28(11):2170-8. doi: 10.1021/acs.chemrestox.5b00327. Epub 2015 Oct 16.

PMID:
26457537
4.

An Integrated Approach for Analysis of the DNA Damage Response in Mammalian Cells: NUCLEOTIDE EXCISION REPAIR, DNA DAMAGE CHECKPOINT, AND APOPTOSIS.

Choi JH, Kim SY, Kim SK, Kemp MG, Sancar A.

J Biol Chem. 2015 Nov 27;290(48):28812-21. doi: 10.1074/jbc.M115.690354. Epub 2015 Oct 5.

PMID:
26438822
5.

Resistance to Nucleotide Excision Repair of Bulky Guanine Adducts Opposite Abasic Sites in DNA Duplexes and Relationships between Structure and Function.

Liu Z, Ding S, Kropachev K, Jia L, Amin S, Broyde S, Geacintov NE.

PLoS One. 2015 Sep 4;10(9):e0137124. doi: 10.1371/journal.pone.0137124. eCollection 2015. Erratum in: PLoS One. 2015;10(10):e0142068. Lei, Jia [corrected to Jia, Lei].

6.

Structural insights into the recognition of cisplatin and AAF-dG lesion by Rad14 (XPA).

Koch SC, Kuper J, Gasteiger KL, Simon N, Strasser R, Eisen D, Geiger S, Schneider S, Kisker C, Carell T.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8272-7. doi: 10.1073/pnas.1508509112. Epub 2015 Jun 22.

7.

Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer.

Rose MC, Kostyanovskaya E, Huang RS.

Genomics Proteomics Bioinformatics. 2014 Oct;12(5):198-209. doi: 10.1016/j.gpb.2014.10.003. Epub 2014 Oct 28. Review.

8.

Structural basis for the recognition of diastereomeric 5',8-cyclo-2'-deoxypurine lesions by the human nucleotide excision repair system.

Kropachev K, Ding S, Terzidis MA, Masi A, Liu Z, Cai Y, Kolbanovskiy M, Chatgilialoglu C, Broyde S, Geacintov NE, Shafirovich V.

Nucleic Acids Res. 2014 Apr;42(8):5020-32. doi: 10.1093/nar/gku162. Epub 2014 Mar 10.

9.

Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.

Zhou W, Chen YW, Liu X, Chu P, Loria S, Wang Y, Yen Y, Chou KM.

PLoS One. 2013 Dec 20;8(12):e83978. doi: 10.1371/journal.pone.0083978. eCollection 2013.

10.
11.

Advances in understanding the complex mechanisms of DNA interstrand cross-link repair.

Clauson C, Schärer OD, Niedernhofer L.

Cold Spring Harb Perspect Biol. 2013 Oct 1;5(10):a012732. doi: 10.1101/cshperspect.a012732. Review.

12.

Binding interaction of HMGB4 with cisplatin-modified DNA.

Park S, Lippard SJ.

Biochemistry. 2012 Aug 28;51(34):6728-37. Epub 2012 Aug 17.

13.

On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapy.

Gómez-Ruiz S, Maksimović-Ivanić D, Mijatović S, Kaluđerović GN.

Bioinorg Chem Appl. 2012;2012:140284. doi: 10.1155/2012/140284. Epub 2012 Jul 12.

14.

Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis.

Enoiu M, Jiricny J, Schärer OD.

Nucleic Acids Res. 2012 Oct;40(18):8953-64. doi: 10.1093/nar/gks670. Epub 2012 Jul 18.

15.

Mitochondrial DNA damage and its consequences for mitochondrial gene expression.

Cline SD.

Biochim Biophys Acta. 2012 Sep-Oct;1819(9-10):979-91. doi: 10.1016/j.bbagrm.2012.06.002. Epub 2012 Jun 19. Review.

16.

Personalized therapy for non-small cell lung cancer: which drug for which patient?

Villaruz LC, Socinski MA.

Semin Thorac Cardiovasc Surg. 2011 Winter;23(4):281-90. doi: 10.1053/j.semtcvs.2012.01.001. Review.

17.

DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

Wang LE, Yin M, Dong Q, Stewart DJ, Merriman KW, Amos CI, Spitz MR, Wei Q.

J Clin Oncol. 2011 Nov 1;29(31):4121-8. doi: 10.1200/JCO.2010.34.3616. Epub 2011 Sep 26.

18.

Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin.

Neher TM, Bodenmiller D, Fitch RW, Jalal SI, Turchi JJ.

Mol Cancer Ther. 2011 Oct;10(10):1796-806. doi: 10.1158/1535-7163.MCT-11-0303. Epub 2011 Aug 16.

19.

Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Roth JA, Carlson JJ.

Clin Lung Cancer. 2011 Nov;12(6):393-401. doi: 10.1016/j.cllc.2011.04.005. Epub 2011 Jul 1. Review.

20.

XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase.

Fuss JO, Tainer JA.

DNA Repair (Amst). 2011 Jul 15;10(7):697-713. doi: 10.1016/j.dnarep.2011.04.028. Epub 2011 May 14. Review.

Items per page

Supplemental Content

Write to the Help Desk